Caricamento...
A Comprehensive Review of Pacritinib in Myelofibrosis
The first-in-class JAK1/JAK2 inhibitor ruxolitinib inhibits JAK/STAT signaling, inducing durable reductions in splenomegaly and constitutional symptoms in patients with myelofibrosis. However, the association of ruxolitinib therapy with myelosuppression indicates the continued need for optimal treat...
Salvato in:
| Pubblicato in: | Future Oncol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918816/ https://ncbi.nlm.nih.gov/pubmed/26367195 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.15.200 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|